Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2026)

Denali Therapeutics has reported Share-based Compensation over the past 9 years, most recently at $24.0 million for Q4 2025.

  • Quarterly Share-based Compensation fell 4.49% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.6 million through Dec 2025, down 3.15% year-over-year, with the annual reading at $99.6 million for FY2025, 3.15% down from the prior year.
  • Share-based Compensation was $24.0 million for Q4 2025 at Denali Therapeutics, down from $25.1 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $28.1 million in Q1 2023 and troughed at $21.0 million in Q3 2021.
  • The 5-year median for Share-based Compensation is $25.1 million (2024), against an average of $24.8 million.
  • Year-over-year, Share-based Compensation soared 94.97% in 2021 and then fell 9.63% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $22.1 million in 2021, then rose by 14.05% to $25.2 million in 2022, then increased by 3.18% to $26.0 million in 2023, then fell by 3.5% to $25.1 million in 2024, then fell by 4.49% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Share-based Compensation are $24.0 million (Q4 2025), $25.1 million (Q3 2025), and $25.4 million (Q2 2025).